Derma Sciences to Present at Two Upcoming Conferences

PRINCETON, N.J.--(BUSINESS WIRE)--Nov 30, 2012--Derma Sciences, Inc. (Nasdaq: DSCI), a medical device and pharmaceutical company focused on advanced wound care, announced today that Edward J. Quilty, the Company’s chief executive officer, will present a corporate overview and update at two conferences in December. They are: To listen and view the presentations investors may visit the investor relations section of Derma Sciences’ website at www.dermasciences.com [1]. Archived copies of the presentations will also be available on Derma Sciences’ website.

About Derma Sciences, Inc. Derma Sciences is a medical technology company focused on three segments of the wound care marketplace: pharmaceutical wound care products, advanced wound care dressings and traditional dressings. Derma Sciences has successfully completed a Phase 2 clinical trial in diabetic foot ulcer healing with DSC127, an investigational pharmaceutical drug under development for the healing of diabetic foot ulcers, and is preparing to begin Phase 3 clinical trials. Its MEDIHONEY® product is the leading brand of honey-based dressings for the management of wounds and burns. The product has been shown to be effective in a variety of indications, and was the focus of a positive large-scale, randomized controlled trial involving 108 subjects with leg ulcers. Other novel products introduced into the $14 billion global wound care market include XTRASORB® for better management of wound exudate, BIOGUARD® for infection prevention and TCC-EZ™, a gold-standard treatment for diabetic foot ulcers.

For more information please visit www.dermasciences.com [1].

CONTACT: Derma Sciences, Inc.

Barry J. Wolfenson, 609-514-4744 Executive Vice President, Global Marketing and Development bwolfenson@dermasciences.com [2] or LHA, Inc.

Investors Kim Sutton Golodetz, 212-838-3777 kgolodetz@lhai.com [3] or Bruce Voss, 310-691-7100 bvoss@lhai.com [4] @LHA_IR_PR or SpecOps Communicaitons Media Mackenzie Mills, 212-518-7721 / Cell: 913-558-2492 mackenzie@specopscomm.com [5] @SpecOpsComm KEYWORD: UNITED STATES NORTH AMERICA NEW JERSEY NEW YORK INDUSTRY KEYWORD: HEALTH BIOTECHNOLOGY CLINICAL TRIALS PHARMACEUTICAL DIABETES MEDICAL SUPPLIES SOURCE: Derma Sciences, Inc. Copyright Business Wire 2012 PUB: 11/30/2012 02:29 PM/DISC: 11/30/2012 02:29 PM http://www.businesswire.com/news/home/20121130005812/ [6]